<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002172</url>
  </required_header>
  <id_info>
    <org_study_id>093</org_study_id>
    <secondary_id>901</secondary_id>
    <nct_id>NCT00002172</nct_id>
  </id_info>
  <brief_title>An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml</brief_title>
  <official_title>An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Immune Response Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To provide product through an expanded access program to HIV-infected patients with CD4&#xD;
      counts less than 300 cells/ml.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 Immunogen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-1 seropositivity.&#xD;
&#xD;
          -  CD4 counts &lt; 300 cells/ml.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  If a patient's CD4 count is 275 to 300 cells/ml, the patient must either rescreen for&#xD;
             Study 806 or wait 6 months before entering the expanded access program.&#xD;
&#xD;
          -  Patient must have failed or been intolerant to other comparable or alternative&#xD;
             marketed therapies or must not be a candidate for such therapies.&#xD;
&#xD;
          -  Patient must not meet inclusion criteria for other Remune trials.&#xD;
&#xD;
          -  Patient must have laboratory tests within specified limits.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Clinically significant cardiac, hepatic, renal, or gastrointestinal dysfunction.&#xD;
&#xD;
          -  Current participation in a Remune study.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Use of any immune-modulating drugs.&#xD;
&#xD;
          -  Induction therapy or initiation of new treatment regimen for an AIDS-defining&#xD;
             condition.&#xD;
&#xD;
        Patients with any of the following prior conditions are excluded:&#xD;
&#xD;
        Previous participation in a Remune study.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Use of any immune-modulating drugs within 3 months of Day 1 visit.&#xD;
&#xD;
          -  Induction therapy or initiation of new treatment regimen for an AIDS-defining&#xD;
             condition within 30 days of Day 1 visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Immune Response Corp</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS Vaccines</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>Salk HIV Immunogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

